Thor Equities.
Thor Equities announced that Noreen Ehrlich Ehr·lich , Paul 1854-1915.
German bacteriologist who conducted pioneering research in chemotherapy and developed the chemical Salvarsan as a treatment of syphilis. has joined the firm as executive vice president and chief financial officer. In her new position, Ehrlich will be responsible for financing, infrastructure development and investor relations Investor relations
The process by which the corporation communicates with its investors. .
Prior to joining Thor Equities, Ehrlich served as chief financial officer of Aetos Capital Asia Fund.
Ehrlich holds a B.B.A. in accounting from Adelphi University Adelphi University (ədĕl`fī), at Garden City, N.Y.; coeducational; chartered 1896 as Adelphi College. Originally in Brooklyn, the school moved to its present location in 1929 and in 1963 achieved university status. and an M.S. in accounting.
COPYRIGHT 2004 Hagedorn Publication
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion